News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
|
Followers
|
12
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
727
|
|
Created
|
09/18/18
|
Type
|
Free
|
| Moderators | |||
TEL AVIV, Israel and BETHESDA, Maryland, Sept. 18, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that its partner, Eroll Grow Tech (Seedo), has acquired the majority of shares in GRCR partners, which is publicly traded on the OTC market under the symbol GRCR, as announced yesterday.
According to the transaction agreement, Eroll Grow Tech Ltd. (Seedo) will merge its operational activities into GRCR. Cannabics Pharmaceuticals, which provided funds for the transaction, shall eventually receive 13.6% of the merged company, along with a Promissory Note of $350,000 debt owed by Seedo.
"Our involvement with Seedo is continuing to grow. We are glad to see the optimistic responses we are receiving in from both potential partners as well as the media to what we believe will revolutionize personalized medical marijuana," said Eyal Barad, CEO of Cannabics Pharmaceuticals.
"We are also moving ahead with our vision as a part of the platform to build commercialized automated growing platforms to be able to guarantee stable, consistent pharmaceutical grade cannabis worldwide."
"Cannabics Pharmaceuticals will be a very active partner in the development of an automated platform for personalized medical cannabis home grow," Zohar Levy, Seedo's CEO, said: "We thank Cannabics Pharmaceuticals for their trust in our vision and in our company. We have now concluded our pre-order phase and will soon commence delivery."
About Cannabics Pharmaceuticals Inc.
Cannabics Pharmaceuticals Inc. (CNBX) is a U.S public company that has developed a platform which leverages novel drug-screening tools and artificial intelligence to develop cannabinoid-based therapies for cancer that are more precise to a patient's genetic profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer.
About Seedo
Seedo is an Israeli company with Subsidiaries in the US and Europe, that developed the world's first fully-automated device managed and controlled by an artificial intelligent algorithm and monitored by smart phone App. Seedo lets consumers grow their own herbs and vegetables in the comfort of their own home, effortlessly. Seedo controls and monitors the growing process, from seed to plant, while providing optimal lab conditions to assure premium quality produce year-round. Company goal is to simplify the growing process, making it accessible for everyone, with no compromising on quality. Visit Seedo at: www.seedolab.com.
| HokieHead's Simple Valuation | |||||||
| 2019 Units Sold | Units Per Month | Units per 50 US States only per month | Projected 2019 Sales | COGS (30%) | OpEx (40%) | Income | PPS with 25 PE |
| 1,000 | 83 | 20 | $ 2,000,000 | $ 600,000 | $ 800,000 | $ 600,000 | $ 1.00 |
| 10,000 | 833 | 200 | $ 20,000,000 | $ 6,000,000 | $ 8,000,000 | $ 6,000,000 | $ 10.00 |
| 25,000 | 2,083 | 500 | $ 50,000,000 | $ 15,000,000 | $ 20,000,000 | $ 15,000,000 | $ 25.00 |
| 50,000 | 4,167 | 1,000 | $ 100,000,000 | $ 30,000,000 | $ 40,000,000 | $ 30,000,000 | $ 50.00 |
